David Pascoe

David Pascoe started the Rosacea Support Group in October 1998.

retinaldehyde may reduce VEGF

Written by on August 18, 2005 in research, VEGF with 1 Comment

From Skin and Allergy News, July 2005, Think Outside the Box for Rosacea Tx Options. Cherie Detrie, M.D., director of cosmetic dermatology at the University of Pennsylvania in Radnor, said “the retinaldehyde offers rosacea patients who may have sensitive skin the benefits of retinoids with fewer side effects.” She described the formulation as a “way […]

Continue Reading

Dr. Sy and Dr. Soldo join the RRF MAC

Written by on August 16, 2005 in research foundation with 7 Comments

The Rosacea Research Foundation has announced that Dr. Linda Sy and Dr. Nicholas Soldo have agreed to join the Foundation’s Medical Advisory Committee. Many will know Dr. Linda Sy MD as a dermatologist from her involvement with The Rosacea Support Group and her skincare range. Dr. Nicholas Soldo MD is known for his expertise in […]

Continue Reading

Micronized Zinc Oxide Dimethicone a Safe Sunscreen

Written by on August 15, 2005 in Sunscreens for Rosacea Sufferers with 11 Comments

There has been some concern amoungst rosacea sufferers about possible health problems with micronized zinc oxide and titanium dioxide. An article was published in 1997 with an alarmist title “Titanium Dioxide/Zinc Oxide nanoparticles from sunscreen are found to cause free radicals in skin cells, damaging DNA” Oxford University and Montreal University, Dunford, Salinaro et al. […]

Continue Reading

mexoryl: sunscreen with good UVA filtering

Written by on August 12, 2005 in Sunscreens for Rosacea Sufferers with 0 Comments

It is well understood that for good sun protection both UVA and UVB needs to be blocked. As the sun is a trigger for many rosacea sufferers, good sun protection is a must. Lets look at Mexoryl. Mexoryl SX (patented by L’Oreal) is a photostable UVA filter that is used in sunscreens available in many […]

Continue Reading

COL-3 new tetracycline derivative being studied

Written by on August 11, 2005 in tetracyclines with 0 Comments

A new anti-inflammatory compound has had some Phase 2 Clinical information published. COL-3 is a so called second generation IMPACS (Inhibitors of Multiple Proteases and Cytokines) compound. It is a tetracycline derivate, and is also designated as a Synthetic MMP (Matrix Metalloproteinsase) inhibitor. Guy Webster, MD. PhD the lead investigator for these Phase 2 clinical […]

Continue Reading

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.